Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Würselen – page 46

1 367 clinical trials in Würselen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Würselen at a glance
1 367
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 367 trials in Würselen

Open in trial search

Study on Long-Term Safety of Secukinumab for Patients with Psoriatic Arthritis, Ankylosing Spondylitis, and Severe Chronic Plaque Psoriasis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Study on Early Use of Candesartan vs Placebo for People with Genetic Risk of Dilated Cardiomyopathy

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Candesartan Cilexetil
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario Puerta De Hierro Majadahonda

Medulloblastoma

Recruiting

Study on the Effectiveness of Bevacizumab and Drug Combination for Children with Recurrent or Progressive Medulloblastoma, Ependymoma, and ATRT

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Bevacizumab
  • Sponsor:Medical University Of Vienna

Study on Tioguanine and Drug Combination for Patients Aged 0-45 with Newly Diagnosed Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Blinatumomab
  • Sponsor:Karolinska University Hospital

Breast cancer+2

Recruiting

Study Comparing Trastuzumab Deruxtecan with a Drug Combination for Patients with HER2+ Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:WSG Women's Cancer Study Group GmbH

Myelofibrosis+1

Recruiting

Study on Tasquinimod for Patients with Myelofibrosis Who Are Refractory or Intolerant to JAK2 Inhibitors

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Tasquinimod
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Gilead Sciences Inc.

Study Comparing Venetoclax and Azacitidine with Standard Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia Patients with NPM1 Mutations Eligible for Intensive Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Technische Universitat Dresden

Study on Blinatumomab, Ponatinib, and Isatuximab for Adults Aged 18-65 with Newly Diagnosed Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Assistance Publique Hopitaux De Paris

Study on Docetaxel, Cabazitaxel, and Darolutamide for Men with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cabazitaxel
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Study on Timing of Chemotherapy with Paclitaxel Albumin-Bound and Drug Combination for Patients with Metastatic Pancreatic Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Amsterdam UMC Stichting

Study on the Effectiveness of Oxaliplatin, Docetaxel, and Fluorouracil in Patients with Resectable Gastric and Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Krankenhaus Nordwest GmbH

Other cities in Germany

The busiest research cities in the country

All 503 cities in Germany

Clinical research in Würselen

What the registry says about research in the country

01 Urological Oncology

Innovative research focusing on non-muscle invasive bladder cancer, evaluating combination therapies including immunotherapy approaches. These trials aim to improve treatment outcomes and reduce recurrence rates.

  • BCG Combination Therapy
  • Novel Immunotherapy Approaches
  • Disease-Free Survival Studies

Examining alternative treatment options including natural compounds for bladder cancer management.

02 Hematologic Disorders

Advanced research into polycythemia vera treatment resistance, utilizing artificial intelligence to predict therapeutic outcomes. Studies focus on optimizing hydroxyurea treatment protocols.

  • AI-Driven Treatment Prediction
  • Drug Resistance Analysis
  • Personalized Medicine Approaches

Integration of machine learning technologies to enhance treatment effectiveness.

03 Prostate Cancer Research

Comparative studies evaluating different dosing regimens for metastatic prostate cancer treatments, focusing on optimizing therapeutic combinations while minimizing adverse effects.

  • Treatment Safety Profiles
  • Dosing Schedule Optimization
  • Combination Therapy Assessment

Investigating innovative approaches to enhance treatment tolerability and effectiveness.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.